Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–242.
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, et al. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. Immunity. 2007 July;27(1):111–122.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–772.
   PubMed Web of Science ®Google Scholar
• Kinter AL, Godbout EJ, McNally JP, et al. The common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed Death-1 and Its ligands. J Immunol. 2008 Nov;181(10):6738–6746.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010 Oct;116(17):3268–3277.
   PubMed Web of Science ®Google Scholar
• Li F, Ren Y, Wang Z. Programmed death 1 ligand 1 expression in breast cancer and its association with patients’ clinical parameters. J Cancer Res Ther. 2018;14(1):150–154.
   PubMed Web of Science ®Google Scholar
• Tamura H, Ishibashi M, Yamashita T, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013 Feb;27(2):464–472.
   PubMed Web of Science ®Google Scholar
• Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307–314.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. .
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461. [ Cell Press].
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). MDPI AG. 2020;12:738.
   Web of Science ®Google Scholar
• Sun L, Zhang L, Yu J, et al. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2083.
   PubMed Web of Science ®Google Scholar
• S E, S H, G P, et al. Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014;33:9.
   Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 April;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Sundar R, Huang KK, Qamra A, et al. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Ann Oncol. 2019 Mar;30(3):424–430.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016 Mar;351(6280):1463–1469.
   PubMed Web of Science ®Google Scholar
• Eckstein M, Gupta S. New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story? Ann Trans Med. 2019 July;7(S3):S135–S135.
   PubMedGoogle Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 September;313(5795):1960–1964.
   PubMed Web of Science ®Google Scholar
• Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer. [ Nature Publishing Group. 2017;117:1–7.
   PubMed Web of Science ®Google Scholar
• Veldman J, Visser L, Van Denberg A, et al. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma. Cancer Treat Rev. 2020;82:101931. [ W.B. Saunders Ltd].
   PubMed Web of Science ®Google Scholar
• Zhang X, Schwartz JCD, Guo X, et al. Structural and functional analysis of the costimulatory receptor programmed Death-1. Immunity. 2004 Mar;20(3):337–347.
   PubMed Web of Science ®Google Scholar
• Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch Motif of programmed Death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004 July;173(2):945–954.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000 October;192(7):1027–1034. .
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed Death 1 ligands by Murine T cells and APC. J Immunol. 2002 November;169(10):5538–5545. .
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM Motif-carrying immunoreceptor. Immunity. 1999;11(2):141–151.
   PubMed Web of Science ®Google Scholar
• Carter LL, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol. 2002;32(3):634–643.
   PubMed Web of Science ®Google Scholar
• Zeng T, Qin Q, Bian Z, et al. Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). Artif Cells Nanomed Biotechnol. 2019 December;47(1):4194–4201.
   PubMed Web of Science ®Google Scholar
• Wang BC, Zhang ZJ, Fu C, et al. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Medicine (USA). 2019 Nov;98:47.
   Google Scholar
• Pezeshki PS, Eskian M, Hamblin MR, et al. Immune checkpoint inhibition in classical Hodgkin lymphoma Internet. Expert Rev Anticancer Ther. 2021. Apr 15;null-null. doi:https://doi.org/10.1080/14737140.2021.1918548 1–14.
   Google Scholar
• Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and Tolerability of PD‐1/PD‐L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: a Meta‐Analysis. Oncologist. 2017 April;22(4):470–479.
   PubMed Web of Science ®Google Scholar
• Wang C, Yu X, Wang W. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. Medicine (USA). 2016;95:52.
   Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Eng J Med. 2012 June;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Wang DY, Johnson DB, Davis EJ. Toxicities associated with PD-1/PD-L1 blockade. Cancer J. 2018 January;24(1):36–40.
   PubMed Web of Science ®Google Scholar
• Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell Death 1 inhibitor–Related pneumonitis in patients with advanced cancer. JAMA Oncol. 2016 December 1;2(12):1607.
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019 September 15;16(9):563–580.
   PubMed Web of Science ®Google Scholar
• Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016 April 2;7(1). DOI:https://doi.org/10.1038/ncomms10391.
   Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with combination immune checkpoint blockade. New Eng J Med. 2016 November 3;375(18):1749–1755.
   Web of Science ®Google Scholar
• Boon T, Cerottini J-C, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994 April;12(1):337–365.
   PubMedGoogle Scholar
• Tahara K, Mori M, Sadanaga N, et al. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer. 1999 March;85(6):1234–1240.
   PubMed Web of Science ®Google Scholar
• Mulcahy KA, Rimoldi D, Brasseur F, et al. Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer. 1996 June;66(6):738–742. .
   PubMed Web of Science ®Google Scholar
• Russo V, Traversari C, Verrecchia A, et al. Expression of the mage gene family in primary and metastatic human breast cancer: implications for tumor antigen‐specific immunotherapy. Int J Cancer. 1995;64(3):216–221.
   PubMed Web of Science ®Google Scholar
• Tanaka F, Mori M, Li J, et al. High frequency of the expression of the MAGE gene family in human esophageal carcinoma. Int J Oncol. 1997;10(6):1113–1117.
   PubMed Web of Science ®Google Scholar
• Eura M, Ogi K, Chikamatsu K, et al. Expression of the MAGE gene family in human head‐and‐neck squamous‐cell carcinomas. Int J Cancer. 1995;64(5):304–308.
   PubMed Web of Science ®Google Scholar
• Tsang CM, Tsao SW. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Virol Sin. 2015;30:107–121. [ Science Press].
   PubMed Web of Science ®Google Scholar
• Tsao SW, Tsang CM, To KF, et al. The role of Epstein-Barr virus in epithelial malignancies. J Pathol. 2015 January;235(2):323–333.
   PubMed Web of Science ®Google Scholar
• Shibata T, Lieblong BJ, Sasagawa T, et al. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019;78:8–16. [ W.B. Saunders Ltd].
   PubMed Web of Science ®Google Scholar
• Knocke S, Fleischmann-Mundt B, Saborowski M, et al. Tailored tumor immunogenicity reveals regulation of CD4 and CD8 T cell responses against Cancer. Cell Rep. 2016;17(9):2234–2246.
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Coulie PG, Gilboa E, et al. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12(4):307–313. NIH Public Access.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New Eng J Med. Internet. 2015 May 30;372(26):2509–2520. 2015 June.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY). 2017 July;357(6349):409–413. .
   Google Scholar
• Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017 May;545(7652):60–65.
   PubMed Web of Science ®Google Scholar
• Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data Internet. Bioinformatics. 2013 December 25;30(7):1015–1016. 2014 Apr.
   PubMed Web of Science ®Google Scholar
• Mandal R, Samstein RM, Lee K-W, et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response Internet. Science (New York, NY). 2019 May;364(6439):485–491. Available from: https://pubmed.ncbi.nlm.nih.gov/31048490
   Google Scholar
• Dudley JC, Lin M-T, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016 February;22(4):813–820.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017 April;9(1):34.
   PubMed Web of Science ®Google Scholar
• Castro F, Cardoso AP, Gonçalves RM, et al. Interferon-Gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018 May;9:847.
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1/2. mutations. Cancer Discov. 2017 February;7(2): 188 LP – 201.
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an Interferon-dependent tumor surveillance system in immunocompetent Mice. Proc Nat Acad Sci USA. 1998;95(13):7556–7561.
   PubMed Web of Science ®Google Scholar
• Zhang S, Kohli K, Black RG, et al. Systemic interferon-γ increases MHC class i expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial. Cancer Immunol Res. 2019 August;7(8):1237–1243. .
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Kaklamanis L, Pezzella F, et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 1996;73(2):148–153.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Gusenleitner D, Jackson DG, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. Internet. 2018 July;10(450):eaar3342. Available from: http://stm.sciencemag.org/content/10/450/eaar3342.abstract
   PubMed Web of Science ®Google Scholar
• Shklovskaya E, Lee JH, Lim SY, et al. Tumor MHC expression guides first-line immunotherapy selection in melanoma. Cancers (Basel). 2020;12:3374.
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234:8509–8521. [ Wiley-Liss Inc.].
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ertl HCJ. Starved and asphyxiated: how can CD8+ T cells within a tumor microenvironment prevent tumor progression. Front Immunol. 2016;7(FEB). DOI:https://doi.org/10.3389/fimmu.2016.00032
   Google Scholar
• Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell–derived lactic acid on human T cells. Blood. 2007;109(9):3812-9. ashpublications.org
   Google Scholar
• Gide TN, Quek C, Menzies AM, et al. Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy. Cancer Cell. 2019 February;35(2):238–255. e6.
   PubMed Web of Science ®Google Scholar
• Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016 November;22(22):5487–5496.
   PubMed Web of Science ®Google Scholar
• Diem S, Kasenda B, Spain L, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. 2016 February;114(3):256–261.
   PubMed Web of Science ®Google Scholar
• Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016 November;24(5):657–671.
   PubMed Web of Science ®Google Scholar
• Maleki Vareki S, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017;116:116–124. [ Elsevier Ireland Ltd].
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015 July;523(7559):231–235.
   PubMed Web of Science ®Google Scholar
• Pai SG, Carneiro BA, Mota JM, et al. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10(1):101. .
   PubMedGoogle Scholar
• Xue J, Yu X, Xue L, et al. Intrinsic β-catenin signaling suppresses CD8 + T-cell infiltration in colorectal cancer. Biomed Pharmacother. 2019 July;115:108921.
   Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–615.
   PubMed Web of Science ®Google Scholar
• Siddiqui I, Schaeuble K, Chennupati V, et al. Intratumoral Tcf1 + PD-1 + CD8 + T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019 January;50(1):195–211. e10.
   PubMed Web of Science ®Google Scholar
• Wei SC, Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade. Cell. 2017 September;170(6):1120–1133. e17.
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Rowswell-Turner RB, Gu T, et al. Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis. J Immunol (Baltimore, Md). 1950 December;183(12):7656–7660.
   Google Scholar
• Algazi AP, Twitty CG, Tsai KK, et al. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clin Cancer Res. 2020 June;26(12):2827–2837.
   PubMed Web of Science ®Google Scholar
• Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276:97–111. Blackwell Publishing Ltd.
   PubMed Web of Science ®Google Scholar
• Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol. 2013;13(11):777–789.
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Takemoto N, Wherry EJ, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol. 2005;6(12):1236–1244.
   PubMed Web of Science ®Google Scholar
• Granier C, Dariane C, Combe P, et al. Tim-3 expression on tumor-infiltrating PD-1+CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma. Cancer Res. 2017 March;77(5):1075–1082.
   PubMed Web of Science ®Google Scholar
• Muenst S, Soysal SD, Gao F, et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013 June;139(3):667–676.
   PubMed Web of Science ®Google Scholar
• Richendollar BG, Pohlman B, Elson P, et al. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Human Pathol. 2011 April;42(4):552–557.
   PubMed Web of Science ®Google Scholar
• Kansy BA, Concha-Benavente F, Srivastava RM, et al. PD-1 status in CD8+ T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res. 2017 November;77(22):6353–6364.
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018 November;175(4):998–1013. e20.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018 May;557(7706):575–579.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018 July;8(7): 822 LP – 835.
   Web of Science ®Google Scholar
• Kim C, Kim E, Jung H, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016;16(1): Springer. doi:https://doi.org/10.1186/s12885-016-2451-6.
   Google Scholar
• Kim H, Lee J, Lim S, et al. Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat. 2016;48:527–536.
   Web of Science ®Google Scholar
• Ness N, Andersen S, Khanehkenari MR. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget. 2017;8(16):26789–26801. ncbi.nlm.nih.gov
   Google Scholar
• Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015 November;9(9):1773–1782.
   PubMed Web of Science ®Google Scholar
• Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013 July;19(13):3462–3473.
   PubMed Web of Science ®Google Scholar
• Cierna Z, Mego M, Miskovska V, et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol. 2016 February;27(2):300–305.
   PubMed Web of Science ®Google Scholar
• Li X, Li M, Lian Z, et al. Prognostic role of programmed death ligand-1 expression in breast cancer: a systematic review and meta-analysis. Target Oncol. Springer 2016;11: 753–761.
   Web of Science ®Google Scholar
• Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 April;26(4):812–817.
   PubMed Web of Science ®Google Scholar
• Liu G, Li X, Zhang Y-M. international YZ-C cell. 2019. undefined. Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell Int. Springer. 19. doi:https://doi.org/10.1186/s12935-019-0738-9.
   Google Scholar
• Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol. 2016;2:1217–1222. American Medical Association.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Hatabu H, et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14:655–668. Nature Publishing Group.
   PubMed Web of Science ®Google Scholar
• Li M, Li A, Zhou S, et al. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer. 2018 January;18(1):4.
   PubMedGoogle Scholar
• Pyo J, Kang G. JK-TI journal. 2017. undefined. Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. Int J Biol Markers. 2017;32(1):68-74. journals.sagepub.com
   Google Scholar
• Fumet J, Richard C, Ledys F. QK-B journal. 2018. undefined. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer. 119: 950–960. nature.com
   PubMed Web of Science ®Google Scholar
• Chovanec M, Cierna Z, Miskovska V, et al. U. prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors. Oncotarget. 2017;8:21794–21805.
   Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 November;515(7528):563–567.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 November;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Martin AM, Nirschl TR, Nirschl CJ, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015 December;18(4):325–332.
   PubMed Web of Science ®Google Scholar
• Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020 April;20(4):209–215.
   PubMed Web of Science ®Google Scholar
• Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018 August;560(7718):382–386.
   PubMed Web of Science ®Google Scholar
• Gong B, Kiyotani K, Sakata S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019 April;216(4):982–1000.
   PubMed Web of Science ®Google Scholar
• Shen X, Zhao BZ. 2018.Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. k3529. bmj.com
   Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 April;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol. 2016 August;34(23):2690–2697.
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. American Society of Clinical Oncology 2016;34: 3733–3739.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018 April;36(10):942–950. .
   PubMed Web of Science ®Google Scholar
• Neish AS. Microbes in Gastrointestinal Health and Disease. Gastroenterology. 2009;136:65–80. W.B. Saunders.
   PubMed Web of Science ®Google Scholar
• Bik EM. Composition and function of the human-associated microbiota. Nutr Rev. 2009;67:S164–S171.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 November;350(6264):1084–1089.
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 January;359(6371):104–108.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 January;359(6371):91–97.
   PubMed Web of Science ®Google Scholar
• Jin Y, Dong H, Xia L, et al. The diversity of gut microbiome is associated with favorable responses to anti–programmed Death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019 August;14(8):1378–1389.
   PubMed Web of Science ®Google Scholar
• Nastasi C, Candela M, Bonefeld CM, et al. The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Sci Rep. 2015 November;5. DOI:https://doi.org/10.1038/srep16148
   Google Scholar
• Cremonesi E, Governa V, Garzon JFG, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut. 2018 Nov;67(11):1984–1994.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. New Eng J Med. 2016 September;375(9):819–829.
   PubMed Web of Science ®Google Scholar
• Saleh R, Elkord E. Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 2019 August;457:168–179.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay E, Li Y, et al. U. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7. nature.com
   Web of Science ®Google Scholar
• Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE. 2012 February;7(2):e30676. Bachmann MP, editor.
   PubMed Web of Science ®Google Scholar
• Oweida A, Hararah MK, Phan A, et al. Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration. Clin Cancer Res. 2018 November;24(21):5368–5380.
   PubMed Web of Science ®Google Scholar
• Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004 October;21(4):503–513.
   PubMed Web of Science ®Google Scholar
• Okamura T, Fujio K, Sumitomo S, et al. Roles of LAG3 and EGR2 in regulatory T cells. Ann Rheum Dis. 2012;71:i96–100. BMJ Publishing Group Ltd.
   PubMed Web of Science ®Google Scholar
• Huang RY, Francois A, McGray AR, et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. OncoImmunology. 2017 January;6(1):e1249561.
   PubMed Web of Science ®Google Scholar
• Qin S, Xu L, Yi M, et al., Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 18: BioMed Central Ltd. 2019; doi:https://doi.org/10.1186/s12943-019-1091-2.
   Google Scholar
• Johnson DB, Nixon MJ, Wang Y, et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight. Internet. 2018 December;3(24). doi:https://doi.org/10.1172/jci.insight.120360.
   Web of Science ®Google Scholar
• Davis RS. Roles for the FCRL6 Immunoreceptor in Tumor Immunology. Front Immunol. Internet. 2020 October;11:575175. Available from: https://pubmed.ncbi.nlm.nih.gov/33162991
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004 February;75(2):163–189.
   PubMed Web of Science ®Google Scholar
• Martini M, Testi MG, Pasetto M, et al. IFN-γ-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 2010 April;28(20):3548–3557.
   PubMed Web of Science ®Google Scholar
• Street D, Kaufmann AM, Vaughan A, et al. Interferon-γ enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. Gynecol Oncol. 1997;65(2):265–272.
   PubMed Web of Science ®Google Scholar
• Bach EA, Aguet M, Schreiber RD. THE IFNγ RECEPTOR:a paradigm for cytokine receptor signaling. Annu Rev Immunol. 1997 April;15(1):563–591.
   PubMedGoogle Scholar
• Sucker A, Zhao F, Pieper N, et al. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8(1):15440.
   PubMedGoogle Scholar
• Iannello A, Thompson TW, Ardolino M, et al. Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol. 2016;38:52–58.
   PubMed Web of Science ®Google Scholar
• Van Endert PM, Tampé R, Meyer TH, et al. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity. 1994;1(6):491–500.
   PubMed Web of Science ®Google Scholar
• Lotzniker M, Pavesi F, Marbello L, et al. Beta-2-microglobulin as a tumor marker in solid malignancies. Oncology (Switzerland). 1988;45(3):162–165.
   PubMed Web of Science ®Google Scholar
• Hulpke S, Tampé R. The MHC I loading complex: a multitasking machinery in adaptive immunity. Trends Biochem Sci. 2013;38:412–420. Elsevier Current Trends.
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017 December;8(1):1–11.
   PubMedGoogle Scholar
• Gettinger S, Choi J, Hastings K, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017 December;7(12):1420–1435.
   PubMed Web of Science ®Google Scholar
• Vesely M, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann NY Acad Sci. 2013 May;1284:1–5.
   PubMed Web of Science ®Google Scholar
• Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med. 2004 March;10(3):294–298.
   PubMed Web of Science ®Google Scholar
• Spiotto MT, Schreiber H. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens crosspresented by stromal cells. Cancer Immun. 2005 June
   PubMedGoogle Scholar
• Quezada SA, Peggs KS. Tumor-reactive CD4 + T cells: plasticity beyond helper and regulatory activities. Immunotherapy. 2011;3:915–917.
   PubMed Web of Science ®Google Scholar
• Ishizuka JJ, Manguso RT, Cheruiyot CK, et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature. 2019 January;565(7737):43–48.
   PubMed Web of Science ®Google Scholar
• Anagnostou V, Smith KN, Forde PM, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017 March;7(3):264–276.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019 March 6;16(3):151-167.
   PubMed Web of Science ®Google Scholar